Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Compare ownership costs across dividend ETFs to identify which option offers the best balance of cost, yield, and risk.
22,825 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Gallup's newest Life Evaluation Index shows more american workers struggling than thriving for the first time in the ...
Disney, McDonald’s, Microsoft, and Procter & Gamble now appear oversold despite solid earnings and durable consumer s...
Startale Group announces a $63 million Series A backed by SBI Group and Sony Innovation Fund to accelerate Strium, it...
A New Jersey family faces nearly $300,000 in student debt against a paid-off $450,000 home and a $107k gross income, ...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Anthropic confirms it is testing a new AI model after a data leak exposed its existence. The company says early acces...
Meta Platforms is pursuing a bold $9 trillion valuation by 2031 even after a blistering market setback. The plan hing...
Red Cat Holdings posted a record Q4 revenue of $26.2 million and full-year $40.7 million, but margins stayed thin and...
As 2026 unfolds, investors eye the best blockchain penny stocks for upside amid renewed crypto infrastructure gains. ...
Hyperscale AI demand is tightening packaging capacity. Intel's EMIB-T presents a potential workaround as chip packagi...
Ripple announces a security collaboration with Crypto ISAC to share North Korea-linked threat intel, aiming to streng...